Otis Brawley

Last updated

Otis Webb Brawley
Nationality American
Alma mater University of Chicago, Pritzker School of Medicine
Known forWork on cancer
AwardsKey to St. Bernard Parish, Georgia Cancer Coalition Scholar, Member of the National Academy of Medicine
Scientific career
Fields Oncology and Epidemiology
InstitutionsJohns Hopkins University

Otis Webb Brawley is an American physician and the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He served as Chief Medical and Scientific Officer and Executive Vice President of the American Cancer Society from July 2007 to November 2018. He is board certified in internal medicine and medical oncology and is a Master of the American College of Physicians, Fellow of the American Society of Clinical Oncology, and a Fellow of the American College of Epidemiology. He is a member of the Institute of Medicine now known as the National Academy of Medicine.

Contents

Biography

Brawley is a graduate of University of Chicago, Pritzker School of Medicine. He completed a residency in internal medicine at University Hospitals of Cleveland, Case-Western Reserve University, and a fellowship in medical oncology at the National Cancer Institute. As the chief medical and scientific officer and executive vice president of the American Cancer Society, Brawley is responsible for promoting the goals of cancer prevention, early detection, and quality treatment through cancer research and education. He is Professor of haematology, medical oncology, medicine and epidemiology at Emory University. He is also a medical consultant to the Cable News Network (CNN). [1] From 2001 to 2007, he was medical director of the Georgia Cancer Center for Excellence at Grady Memorial Hospital in Atlanta, and deputy director for cancer control at the Winship Cancer Institute at Emory University. He has also previously served as a member of the Society's Prostate Cancer Committee, co-chaired the U.S. Surgeon General's Task Force on Cancer Health Disparities, and filled a variety of positions at the National Cancer Institute (NCI), most recently serving as assistant director. Brawley serves on the Board of Regents of the Uniformed Services University of the Health Sciences. He has served as a member of the Food and Drug Administration Oncologic Drug Advisory Committee, the Centers for Disease Control and Prevention Breast and Cervical Cancer Early Detection and Control Advisory Committee and chaired the NIH Consensus Panel on the Treatment of Sickle Cell Disease. Among numerous other awards, he was a Georgia Cancer Coalition Scholar and received the Key to St. Bernard Parish for his work in the U.S. Public Health Service in the aftermath of Hurricane Katrina. In 2011, Brawley joined the International Prevention Research Institute as Senior Research Fellow. [2] In 2022, he was listed on STAT's inaugural STATUS List, "the most definitive and consequential accounting of important and impactful leaders in the life sciences." [3] [4]

Brawley has published more than 200 scientific articles [5] and he has written a book, How We Do Harm: A Doctor Breaks Ranks About Being Sick in America. [6]

Brawley works to reduce overscreening of medical conditions. [7]

Awards

Brawley's awards include:

Publications

Brawley has more than 30,000 citations in Google Scholar and an h-index of 73. [17]

Highly Cited Articles (more than 1000 citations)

Related Research Articles

<span class="mw-page-title-main">Emil Frei</span> American physician and oncologist

Emil "Tom" Frei III was an American physician and oncologist. He was the former director and former physician-in-chief of the Dana–Farber Cancer Institute in Boston, Massachusetts. He was also the Richard and Susan Smith Distinguished Professor of Medicine at Harvard Medical School.

Graham Andrew Colditz MD, DrPH is an Australian chronic disease epidemiologist. He is the inaugural Niess-Gain Professor at Washington University School of Medicine, where he is associate director for Prevention and Control at the Alvin J. Siteman Cancer Center. He directs the Master of Population Health Science at Washington University School of Medicine. During medical training he was excited by the potential for prevention of chronic diseases. With encouragement from mentors he pursued training in the US as it was routine for academics in Australia to obtain overseas training at that time. He is internationally recognized for leadership in cancer prevention, and is often interviewed by media for input on this topic. With members of Cancer Prevention and Control at Siteman, he blogs on issues relating to cancer prevention and screening. According to Google Scholar statistics, Colditz has a h-index of more than 300.

<span class="mw-page-title-main">Joseph F. Fraumeni Jr.</span> American physician and cancer researcher

Joseph F. Fraumeni Jr. is an American physician and cancer researcher. Born in Boston, he received an A.B. from Harvard College, an M.D. from Duke University, and an M.Sc. in epidemiology from the Harvard School of Public Health. He completed his medical residency at Johns Hopkins Hospital and Memorial Sloan Kettering Cancer Center. He then joined the National Cancer Institute at the National Institutes of Health in 1962 as a commissioned officer of the U.S. Public Health Service, becoming the founding Director of the Division of Cancer Epidemiology and Genetics in 1995. He stepped down from this position in 2012 to become a senior investigator and advisor to the National Cancer Institute.

<span class="mw-page-title-main">Edison Liu</span>

Edison T. Liu is an American chemist who is the former president and CEO of The Jackson Laboratory, and the former director of its NCI-designated Cancer Center (2012-2021). Before joining The Jackson Laboratory, he was the founding executive director of the Genome Institute of Singapore (GIS), chairman of the board of the Health Sciences Authority, and president of the Human Genome Organization (HUGO) (2007-2013). As the executive director of the GIS, he brought the institution to international prominence as one of the most productive genomics institutions in the world.

<span class="mw-page-title-main">Peter Boyle (epidemiologist)</span> British epidemiologist (1951–2022)

Peter Boyle, FRSE FFPH FRCPS(Glas) FRCP(Edin) FMedSci, was a British epidemiologist. He conducted research on globalisation of cancer, where he showed the dramatic increase of cancer in low- and medium income countries.

Paolo Boffetta is an Italian epidemiologist. He is doing research on cancer and other chronic diseases, where he contributed to the understanding of the role of occupation, environment, alcohol, smoking and nutrition in disease development.

<span class="mw-page-title-main">Charles Sawyers</span> American physician-scientist (born 1959)

Charles L. Sawyers is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.

<span class="mw-page-title-main">Olufunmilayo Olopade</span> Nigerian physician

Olufunmilayo I. Olopadeborn in the year 1957, is a Nigerian hematology oncologist, Associate Dean for Global Health and Walter L. Palmer, Distinguished Service Professor in Medicine and Human Genetics at the University of Chicago. She also serves as director of the University of Chicago Hospital's Cancer Risk Clinic.

William K. Oh, is an American medical oncologist, academic and industry leader and expert in the management of genitourinary malignancies, including prostate, renal, bladder and testicular cancers.

Alan D. D'Andrea is an American cancer researcher and the Fuller American Cancer Society Professor of Radiation Oncology at Harvard Medical School. D'Andrea's research at the Dana Farber Cancer Institute focuses on chromosome instability and cancer susceptibility. He is currently the director of the Center for DNA Damage and Repair and the director of the Susan F. Smith Center for Women's Cancer.

<span class="mw-page-title-main">William Kaelin Jr.</span> American Nobel Laureate, Professor of Medicine at Harvard University

William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.

Michael A. Caligiuri is an American physician scientist focused on oncology and immunology. He is currently the president of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. He was elected president of the American Association for Cancer Research, the world's largest cancer research organization, for 2017–2018. He was previously the CEO of the James Cancer Hospital (2008-2017), Director of the Comprehensive Cancer Center (2003-2017), and Director of the Division of Hematology-Oncology (2000-2008) at the Ohio State University. He was elected to the United States National Academy of Medicine in 2018.

Nancy E. Davidson is the executive director and president of Seattle Cancer Care Alliance, senior vice president, director of clinical oncology at Fred Hutchinson Cancer Research Center and head of the Division of Medical Oncology at the University of Washington School of Medicine. She focuses her research on breast cancer treatments and the genes that are mutated in various forms of breast cancer. She was president of American Association for Cancer Research from 2015 to 2016 and president of American Society of Clinical Oncology from 2007 to 2008.

<span class="mw-page-title-main">Daniel Von Hoff</span>

Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen), and current Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute. He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer. He led the development of gemcitabine, and has several drugs in development.

<span class="mw-page-title-main">Curtis C. Harris</span> American cancer researcher

Curtis. C. Harris is the head of the Molecular Genetics and Carcinogenesis Section and chief of the Laboratory of Human Carcinogenesis at the Center for Cancer Research of the National Cancer Institute, NIH.

Joseph Rocco Bertino was a researcher in the cancer pharmacology program at Rutgers Cancer Institute of New Jersey and professor of medicine and pharmacology at the Robert Wood Johnson Medical School in New Jersey. His research is focused on the treatment of lymphoma.

Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.

James R. Downing is an American clinical executive. He is the president and chief executive officer of St. Jude Children's Research Hospital.

Carol L. Brown is the Nicholls-Biondi Chair for Health Equity at Memorial Sloan Kettering Cancer Center and a professor at Weill Cornell Medical College. She is a surgeon known for her work on gynecological cancers.

Philip Greenberg is a Professor of Medicine, Oncology and Immunology at the University of Washington and Head of Program in Immunology at Fred Hutchinson Cancer Research Center. His research is centered around T cell biology and therapeutic cell therapies. He is a co-founder of Juno Therapeutics and Affini-T.

References

  1. ↑ Otis Brawley, Medical Consultant to the CNN
  2. ↑ Otis Brawley at iPRI Archived 24 March 2012 at the Wayback Machine
  3. 1 2 "Washington City Paper - Press Releases". Washington City Paper. 11 February 2022. Retrieved 21 March 2022.
  4. ↑ "BDP Otis Brawley named by STAT as one of the country's most influential science thought leaders". The Hub. 1 March 2022. Retrieved 21 March 2022.
  5. ↑ Otis Brawley's publications in PubMed
  6. ↑ "How We Do Harm", Kirkus Reviews, 28 November 2011.
  7. ↑ Lenzer, Jeanne (2016). "Otis Brawley—one of the first to question the value of screening". BMJ. 353: i2301. doi:10.1136/bmj.i2301. ISSN   1756-1833. PMID   27117310. S2CID   38917899.
  8. ↑ "Atlanta physician honored with Distinguished Service Award". American Medical Association. Retrieved 28 April 2021.
  9. ↑ "Otis W. Brawley, SB'81, MD'85, to deliver Class Day address during Convocation". University of Chicago News. Retrieved 28 April 2021.
  10. ↑ "2018 Annual Report - Maryland State Council on Cancer Control" (PDF). Maryland Department of Health. Retrieved 28 April 2021.
  11. ↑ "Otis W. Brawley, M.D. Elected to National Academy of Medicine". American Cancer Society MediaRoom. Retrieved 28 April 2021.
  12. ↑ "Mastership | Awards, Masterships & Competitions | ACP". www.acponline.org. Retrieved 28 April 2021.
  13. ↑ "Otis W. Brawley, MD | CEO Roundtable on Cancer". www.ceoroundtableoncancer.org. Retrieved 28 April 2021.
  14. ↑ "AACR-MICR Jane Cooke Wright Lectureship | Awards | AACR".
  15. ↑ "Otis W. Brawley, MD, MACP, FASCO". ASCO. Retrieved 28 April 2021.
  16. ↑ "Otis Brawley". The Forum at Harvard T. H. Chan School of Public Health. 10 February 2017. Retrieved 28 April 2021.
  17. ↑ "Otis Brawley". scholar.google.com. Retrieved 11 May 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.